替加环素治疗血液疾病并发感染的疗效

doi:10.3877/cma.j.issn.1674-1358.2016.02.020

目的

探讨替加环素治疗血液疾病并发感染的疗效。

方法

本院2011年1月至2015年1月收治的血液疾病并发感染者共80例，按用药情况分为更换替加环素组（36例）和初始即联合其他抗菌药物组（44例）。两组患者治疗后进行疗效评价，治疗过程观察患者肝肾功能，同时记录其症状、体征的变化和药物不良反应等。

结果

80例患者中发生粒细胞缺乏者26例（32.50%），中性粒细胞缺乏时间为2～65 d，平均（18.5 ± 16.5）d。68例（85.00%）患者发热，发热持续时间1～52 d，平均（10.5 ± 8.5）d。共检测出41株菌株，其中27株（65.85%）革兰阴性菌、13株（31.71%）革兰阳性菌和1株（2.44%）真菌。1株肺炎克雷伯菌对替加环素耐药，耐药率为33.33%，1株凝固酶阴性葡萄球菌对替加环素耐药，耐药率为16.67%，其余菌株均对替加环素敏感。80例患者治愈2例，好转55例（总有效率为71.25%），无效13例，死亡10例。更换替加环素组和初始即联合其他抗菌药物组总有效率分别为72.22%和70.45%，总有效率差异无统计学意义（χ² = 0.265，P > 0.05）。不良反应轻，主要为消化道不适等症状。

结论

替加环素以抗菌谱广、抗菌活性强的特点，可作为血液疾病继发感染者替补方案或经验治疗的选择，具有良好的疗效和安全性。

关键词: 替加环素, 血液疾病, 感染

Objective

To investigate the effect of tigecycline in treatments on patients with blood disease complicated with infection.

Methods

Total of 80 cases with blood diseases and infection in our hospital from January 2011 to January 2015 were divided into changed tigecycline group (36 cases) and originally combined using tigecycline and other antibiotics group (44 cases). The curative efficiency, liver and rental function, symptom and adverse effects were determined, respectively.

Results

There were 26 (32.50%) cases with agranulocytosis for 2-65 d, with the mean time of (18.5 ± 16.5) d. While 68 (85.00%) cases were with fever; the fever time were 1-52 d, with the average of (10.5 ± 8.5) d. Total of 41 strains were detected, including 27 (65.85%) strains of Gram-negative bacteria, 13 strains (31.71%) of Gram-positive bacteria and 1 (2.44%) strain of fungi. One strain of Klebsiella pneumoniae and one strain of coagulase negative Staphylococcus were resistant against tigecycline, with the resistance rate as 33.33% and 16.67%, respectively. Total of 2 patients were cured and 55 cases were improved, with the total effective rate of 71.25%. The total effective rates of tigecycline group and originally combined using tigecycline and other antibiotics group were 72.22% and 70.45%, respectively, with no significant difference (χ² = 0.265, P > 0.05). Adverse reaction was mild due to mostly gastrointestinal symptoms.

Conclusions

Tigecycline, with wide antibiotic spectrum and high antimicrobial activities, could be used as a supplement treatment for patients with blood diseases and infection, with good curative effect and safety.

Key words: Tigecycline, Blood diseases, Infection

表1 病原菌分布及构成比

病原菌		株数	构成比（%）
革兰阴性菌		27	65.85
	鲍曼不动杆菌	9	21.95
	铜绿假单胞菌	7	17.07
	大肠埃希菌	4	9.76
	肺炎克雷伯菌	3	7.32
	洛菲不动杆菌	2	4.88
	嗜麦芽窄食单胞菌	2	4.88
革兰阳性菌		13	31.71
	凝固酶阴性葡萄球菌	6	14.63
	金黄色葡萄球菌	2	4.88
	表皮葡萄球菌	2	4.88
	屎肠球菌	1	2.44
	粪肠球菌	1	2.44
	溶血葡萄球菌	1	2.44
真菌		1	2.44
	热带假丝酵母菌	1	2.44
合计		41	100.00

表1 病原菌分布及构成比

病原菌		株数	构成比（%）
革兰阴性菌		27	65.85
	鲍曼不动杆菌	9	21.95
	铜绿假单胞菌	7	17.07
	大肠埃希菌	4	9.76
	肺炎克雷伯菌	3	7.32
	洛菲不动杆菌	2	4.88
	嗜麦芽窄食单胞菌	2	4.88
革兰阳性菌		13	31.71
	凝固酶阴性葡萄球菌	6	14.63
	金黄色葡萄球菌	2	4.88
	表皮葡萄球菌	2	4.88
	屎肠球菌	1	2.44
	粪肠球菌	1	2.44
	溶血葡萄球菌	1	2.44
真菌		1	2.44
	热带假丝酵母菌	1	2.44
合计		41	100.00

表2 不同组别患者替加环素治愈率比较

组别	例数	治愈（例）	好转（例）	无效（例）	死亡（例）	总有效率（%）
更换替加环素组	36	1	25	6	4	72.22
初始即联合其他抗菌药物组	44	1	30	7	6	70.45

表2 不同组别患者替加环素治愈率比较

组别	例数	治愈（例）	好转（例）	无效（例）	死亡（例）	总有效率（%）
更换替加环素组	36	1	25	6	4	72.22
初始即联合其他抗菌药物组	44	1	30	7	6	70.45

[1]	白丽娜. 成人急性白血病合并医院感染回顾性分析[D]. 石河子: 石河子大学,2013,6.
[2]	刘林辉. 恶性血液病患者医院感染相关因素分析及预防[D]. 乌鲁木齐: 新疆医科大学,2009,3.
[3]	秦慧，汪延生，丁士华, 等. 替加环素治疗免疫力低下的血液病重症感染疗效分析[J]. 安徽医学,2014,35(3):278-282.
[4]	高苏，李正，仇惠英, 等. 替加环素治疗血液病粒细胞缺乏患者感染疗效分析[J]. 中华医院感染学杂志,2014,24(4):860-862.
[5]	王辉，倪语星，陈民钧, 等. 新型廿氨酞环素类抗菌药物替加环素体外药敏试验操作规程[J]. 中华检验医学杂志,2009,32(11):1208-1213.
[6]	蒋春晖. 替加环素抗耐药菌作用的研究进展[J]. 中国药房,2012,23(42):4013-4015.
[7]	Hawser SP, Bouchillon SK, Hackel M, et al. Trending 7 years of in vitro activity of tigecycline and comparators against Gram-positive and Gram-negative pathogens from the Asia-Pacific region: Tigecycline Evaluation Surveillance Trial (TEST) 2004-2010[J]. Int J Antimicrob Agents,2012,39:490-495.
[8]	吴玉红，胡志东，邢莉民, 等. 替加环素治疗血液病患者继发感染的疗效分析[J]. 中华医学杂志,2014,94(34):2669-2672.
[9]	郭晶，张民伟，陈菁, 等. 替加环素治疗多重耐药鲍曼不动杆菌感染的疗效观察[J]. 实用药物与临床,2014,17(9):1131-1135
[10]	Stein GE. New drugs to treat skin and soft tissue infections[J]. Curr Infect Dis Rep,2007,9(5):408.
[11]	Ramirez J, Dartois N, Gandjini H, et al. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia[J]. Antimicrob Agents Chemother,2013,57(4):1756-1762.
[12]	Prasad P, Sun J, Danner RL, et al. Excess deaths associated with tigecycline after approval based on noninferiority trials[J]. Clin Infect Diseases,2012,54(12):1699-1709.
[13]	O’Riordan W, Mehra P, Manos P, et al. A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections[J]. Int J Infect Dis,2015,30:67-73.
[14]	Villa L, Feudi C, Fortini D, et al. Genomics of KPC-producing Klebsiella pneumoniae sequence type 512 clone highlights the role of RamR and ribosomal S10 protein mutations in conferring tigecycline resistance[J]. Antimicrob Agents Chemother,2014,58(3):1707-1712.
[15]	Villa L, Feudi C, Fortini D, et al. Genomics of KPC-producing Klebsiella pneumoniae sequence type 512 clone highlights the role of RamR and ribosomal S10 protein mutations in conferring tigecycline resistance[J]. Antimicrob Agents Chemother,2014,58(3):1707-1712.
[16]	Rossitto G, Piano S, Rosi S, et al. Life-threatening coagulopathy and hypofibrinogenaemia induced by tigecycline in a patient with advanced liver cirrhosis[J]. Eur J Gastroen Hepat,2014,26(6):681-684.
[17]	Bucaneve G, Micozzi A, Picardi M, et al. Results of a multicenter, controlled, randomized clinical trial evaluating the combination of piperacillin/tazobactam and tigecycline in high-risk hematologic patients with cancer with febrile neutropenia[J]. J Clin Oncol,2014,32(14):1463-1471.
[18]	Salem AH, Zhanel GG, Ibrahim SA, et al. Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit-isolated methicillin-resistant Staphylococcus aureus[J]. Clini Exp Pharmacol P,2014,41(6):437-443.
[19]	De Pascale G, Montini L, Pennisi M, et al. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria[J]. Crit Care,2014,18(3):R90.
[20]	Deng M, Zhu MH, Li JJ, et al. Molecular epidemiology and mechanisms of tigecycline resistance in clinical isolates of Acinetobacter baumannii from a Chinese university hospital[J]. Antimicrob Agents Chemother,2014,58(1):297-303.
[21]	Betts JW, Phee LM, Hornsey M, et al. In vitro and in vivo activities of tigecycline-colistin combination therapies against carbapenem-resistant Enterobacteriaceae[J]. Antimicrob Agents Chemother,2014,58(6):3541-3546.

[1]	李培杰, 乔永杰, 张浩强, 曾健康, 谭飞, 李嘉欢, 王静, 周胜虎. 细菌培养阴性的假体周围感染诊治的最新进展[J]. 中华关节外科杂志(电子版), 2023, 17(06): 827-833.
[2]	涂家金, 廖武强, 刘金晶, 涂志鹏, 毛远桂. 严重烧伤患者鲍曼不动杆菌血流感染的危险因素及预后分析[J]. 中华损伤与修复杂志(电子版), 2023, 18(06): 491-497.
[3]	廖锵云, 王震, 林洁玉, 廖夏, 邓锦华, 李杰峰, 邓建维, 李明, 荣新洲. 虎门地区创伤弧菌感染的临床观察[J]. 中华损伤与修复杂志(电子版), 2023, 18(05): 394-398.
[4]	蔡柔妹, 曾洁梅, 黄伟丽, 谢文敏, 刘燕丹, 吴漫君, 蔡楚燕. 利用QC小组干预降低经烧伤创面股静脉置管导管相关性感染发生率的临床观察[J]. 中华损伤与修复杂志(电子版), 2023, 18(05): 399-404.
[5]	杨瑞洲, 李国栋, 吴向阳. 腹股沟疝术后感染的治疗方法探讨[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(06): 715-719.
[6]	徐金林, 陈征. 抗菌药物临床应用监测对腹股沟疝修补术预防用药及感染的影响[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(06): 720-723.
[7]	李静如, 王江玲, 吴向阳. 简易负压引流在腹股沟疝术后浅部感染中的疗效分析[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(06): 745-749.
[8]	李秉林, 吕少诚, 潘飞, 姜涛, 樊华, 寇建涛, 贺强, 郎韧. 供肝灌注液病原菌与肝移植术后早期感染的相关性分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 656-660.
[9]	赵立力, 王魁向, 张小冲, 李志远. 血沉与C-反应蛋白比值在假体周围感染中的诊断价值分析[J]. 中华老年骨科与康复电子杂志, 2023, 09(06): 351-355.
[10]	卓少宏, 林秀玲, 周翠梅, 熊卫莲, 马兴灶. CD64指数、SAA/CRP、PCT联合检测在小儿消化道感染性疾病鉴别诊断中的应用[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 505-509.
[11]	李达, 张大涯, 陈润祥, 张晓冬, 黄士美, 陈晨, 曾凡, 陈世锔, 白飞虎. 海南省东方市幽门螺杆菌感染现状的调查与相关危险因素分析[J]. 中华临床医师杂志(电子版), 2023, 17(08): 858-864.
[12]	卓徐鹏, 刘颖, 任菁菁. 感染性疾病与老年人低蛋白血症的相关性研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(08): 896-899.
[13]	李静静, 翟蕾, 赵海平, 郑波. 多囊肾合并囊肿的多重耐药菌感染一例并文献复习[J]. 中华临床医师杂志(电子版), 2023, 17(08): 920-923.
[14]	李琪, 黄钟莹, 袁平, 关振鹏. 基于某三级医院的ICU多重耐药菌医院感染影响因素的分析[J]. 中华临床医师杂志(电子版), 2023, 17(07): 777-782.
[15]	杨艳丽, 陈昱, 赵若辰, 杜伟, 马海娟, 许珂, 张莉芸. 系统性红斑狼疮合并血流感染的危险因素及细菌学分析[J]. 中华临床医师杂志(电子版), 2023, 17(06): 694-699.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Effect of tigecycline in treatments on patients with blood diseases complicated with infection

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Effect of tigecycline in treatments on patients with blood diseases complicated with infection